APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 INHIBITOR APR-1051 IN PATIENTS WITH ADVAN
APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 I
APREA THERAPEUTICS ANNOUNCES INTERIM RESULTS FROM THE ONGOING FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 I